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Fig. 1. Histological examination of the bladder
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A 85-year-old man achieved complete response after a course of intravesical instillation of Bacillus
Calmette Guerin (BCG) therapy for carcinoma in situ (CIS) of the bladder. Two year later, urine cytology
became class III. We performed random biopsy of the bladder and split urine cytology of the bilateral upper
urinary tract, but none of these examinations revealed any malignant features. After a month, he consulted
orthopedics for lumbago. He was indicated to have a metastatic bone tumor, and positron emission
tomography-computed tomography (PET-CT) showed a hypermetabolic mass in the prostate. A
transperineal needle biopsy of the prostate revealed the urothelial carcinoma (UC). Our diagnosis was
invasion of CIS of the bladder into the prostate. In such cases, we recommend a needle biopsy of the
prostate in addition to a transurethral biopsy of the bladder and prostate.
(Hinyokika Kiyo 60 : 283-286, 2014)






患 者 : 85歳，男性
主 訴 : 腰痛
既往歴 : 特記事項なし
家族歴 : 特記事項なし




診断で膀胱上皮内癌 (urothelial carcinoma in situ，G3，
pTis) と診断された (Fig. 1）．その後，BCG 膀胱内注
入療法（日本株 40 mg× 8回）施行した．2012年 4月











入院時現症 : 身長 162 cm，体重 61.5 kg，表在リン
パ節触知せず，胸腹部理学的所見に異常を認めず，





Fig. 2. PET-CT showed hypermetabolic masses (a :
prostate, b : lung).
泌60,06,05-3
Fig. 3. Histological examination of the prostate
showed high grade urothelial carcinoma
(HE stain).
ECOG performance status 2．
入院時検査所見 : 血液生化学検査では，軽度の貧
血，高 LDH 血症を認めた．腫瘍マーカーを精査した
ところ，CEA 10.8 ng/ml，CA 19-9 1,740 U/ml と高
値を示し，一方で PSA は 0.819 ng/ml と正常範囲内
であった．尿沈渣では赤血球数 1∼4/HPF，白血球数

















経 過 : 2012年12月に経会陰的前立腺針生検を施行
した．
病理学的所見 : 採取された14個の検体の内11個で





































Fig. 4. Immunohistochemically, tumors in the prostate and bladder stained positively for CA 19-9 (a : prostate, b :
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